Research Article
A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway
Table 7
Effect of ruthenium, fluvastatin, and the ruthenium-fluvastatin complex on the expression of Bax, Bcl2, p53, and MMP9 in breast tissues.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||
§Each score represents the results of 6 slides per rat and 6 rats per group (, ). Each field was selected randomly for evaluation of percentage of immune-positive cells. Significant difference between the treated groups and carcinogen control (). Significant difference between the treated groups and carcinogen control (). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||